1. Home
  2. GOOD vs MNPR Comparison

GOOD vs MNPR Comparison

Compare GOOD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Commercial Corporation Real Estate Investment Trust

GOOD

Gladstone Commercial Corporation Real Estate Investment Trust

HOLD

Current Price

$12.86

Market Cap

624.9M

Sector

Real Estate

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$113.63

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOOD
MNPR
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
624.9M
587.4M
IPO Year
2003
2019

Fundamental Metrics

Financial Performance
Metric
GOOD
MNPR
Price
$12.86
$113.63
Analyst Decision
Hold
Strong Buy
Analyst Count
1
11
Target Price
$12.50
$107.00
AVG Volume (30 Days)
324.4K
155.4K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
9.54%
N/A
EPS Growth
N/A
54.99
EPS
0.18
N/A
Revenue
$161,336,000.00
N/A
Revenue This Year
$9.89
N/A
Revenue Next Year
$2.57
N/A
P/E Ratio
$72.72
N/A
Revenue Growth
8.00
N/A
52 Week Low
$10.33
$46.89
52 Week High
$13.28
$124.82

Technical Indicators

Market Signals
Indicator
GOOD
MNPR
Relative Strength Index (RSI) 47.50 50.72
Support Level $12.23 $103.41
Resistance Level $12.92 $114.60
Average True Range (ATR) 0.18 6.38
MACD -0.02 -0.50
Stochastic Oscillator 7.06 49.12

Price Performance

Historical Comparison
GOOD
MNPR

About GOOD Gladstone Commercial Corporation Real Estate Investment Trust

Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: